Yang Y et al. found that ANXA1, as an FPR1 agonist, was more highly expressed in poorly differentiated human primary gliomas compared with lower‐grade tumours, and accounted for stimulating GBM cell growth and invasion.10 This evidence concerns the gene FPR1 and glioblastoma.